Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
ELUTElutia(ELUT) GlobeNewswire News Room·2024-09-06 04:05

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac ...